Longitudinal Changes in Serum Levels of Angiopoietin-Like Protein 6 and Selenoprotein P After Gastric Bypass Surgery

详细信息    查看全文

• 作者：Jisun Lim ; Hye Soon Park ; Seul Ki Lee ; Yeon Jin Jang ; Yeon Ji Lee…
• 关键词：Angiopoietin ; like protein 6 ; Selenoprotein P ; Hepatokine ; Gastric bypass surgery ; Obesity
• 刊名：Obesity Surgery
• 出版年：2016
• 出版时间：April 2016
• 年：2016
• 卷：26
• 期：4
• 页码：825-832
• 全文大小：410 KB
• 参考文献：1.Sjostrom L, Lindroos AK, Peltonen M, et al. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med. 2004;351(26):2683–93.CrossRef PubMed
  2.Puzziferri N, Roshek 3rd TB, Mayo HG, et al. Long-term follow-up after bariatric surgery: a systematic review. JAMA. 2014;312(9):934–42.CrossRef PubMed PubMedCentral
  3.Yu J, Zhou X, Li L, et al. The long-term effects of bariatric surgery for type 2 diabetes: systematic review and meta-analysis of randomized and non-randomized evidence. Obes Surg. 2015;25:143–58.CrossRef PubMed
  4.Rao SR. Inflammatory markers and bariatric surgery: a meta-analysis. Inflamm Res. 2012;61(8):789–807.CrossRef PubMed
  5.Caiazzo R, Lassailly G, Leteurtre E, et al. Roux-en-Y gastric bypass versus adjustable gastric banding to reduce nonalcoholic fatty liver disease: a 5-year controlled longitudinal study. Ann Surg. 2014;260(5):893–9.CrossRef PubMed
  6.Caldwell SH, Crespo DM. The spectrum expanded: cryptogenic cirrhosis and the natural history of non-alcoholic fatty liver disease. J Hepatol. 2004;40(4):578–84.CrossRef PubMed
  7.Hafeez S, Ahmed MH. Bariatric surgery as potential treatment for nonalcoholic fatty liver disease: a future treatment by choice or by chance? J Obes. 2013;2013:839275.CrossRef PubMed PubMedCentral
  8.Stefan N, Haring HU. The role of hepatokines in metabolism. Nat Rev Endocrinol. 2013;9(3):144–52.CrossRef PubMed
  9.Oike Y, Akao M, Yasunaga K, et al. Angiopoietin-related growth factor antagonizes obesity and insulin resistance. Nat Med. 2005;11(4):400–8.CrossRef PubMed
  10.Ebert T, Bachmann A, Lossner U, et al. Serum levels of angiopoietin-related growth factor in diabetes mellitus and chronic hemodialysis. Metabolism. 2009;58(4):547–51.CrossRef PubMed
  11.Misu H, Takamura T, Takayama H, et al. A liver-derived secretory protein, selenoprotein P, causes insulin resistance. Cell Metab. 2010;12(5):483–95.CrossRef PubMed
  12.Yang SJ, Hwang SY, Choi HY, et al. Serum selenoprotein P levels in patients with type 2 diabetes and prediabetes: implications for insulin resistance, inflammation, and atherosclerosis. J Clin Endocrinol Metab. 2011;96(8):E1325–9.CrossRef PubMed
  13.Ko BJ, Kim SM, Park KH, et al. Levels of circulating selenoprotein P, fibroblast growth factor (FGF) 21 and FGF23 in relation to the metabolic syndrome in young children. Int J Obes. 2014;38(12):1497–502.CrossRef
  14.Brix JM, Stingl H, Hollerl F, et al. Elevated Fetuin-A concentrations in morbid obesity decrease after dramatic weight loss. J Clin Endocrinol Metab. 2010;95(11):4877–81.CrossRef PubMed
  15.Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28(7):412–9.CrossRef PubMed
  16.Namkung J, Koh SB, Kong ID, et al. Serum levels of angiopoietin-related growth factor are increased in metabolic syndrome. Metabolism. 2011;60(4):564–8.CrossRef PubMed
  17.Misu H, Ishikura K, Kurita S, et al. Inverse correlation between serum levels of selenoprotein P and adiponectin in patients with type 2 diabetes. PLoS One. 2012;7(4), e34952.CrossRef PubMed PubMedCentral
  18.Zhang Y, Chen X. Reducing selenoprotein P expression suppresses adipocyte differentiation as a result of increased preadipocyte inflammation. Am J Physiol Endocrinol Metab. 2011;300(1):E77–85.CrossRef PubMed PubMedCentral
  19.Labunskyy VM, Lee BC, Handy DE, et al. Both maximal expression of selenoproteins and selenoprotein deficiency can promote development of type 2 diabetes-like phenotype in mice. Antioxid Redox Signal. 2011;14(12):2327–36.CrossRef PubMed PubMedCentral
  20.Rayman MP, Stranges S. Epidemiology of selenium and type 2 diabetes: can we make sense of it? Free Radic Biol Med. 2013;65:1557–64.CrossRef PubMed
  21.Kunutsor SK, Apekey TA, Seddoh D, et al. Liver enzymes and risk of all-cause mortality in general populations: a systematic review and meta-analysis. Int J Epidemiol. 2014;43(1):187–201.CrossRef PubMed
  22.Whitfield JB. Gamma glutamyl transferase. Crit Rev Clin Lab Sci. 2001;38(4):263–355.CrossRef PubMed
  23.Evans JL, Goldfine ID, Maddux BA, et al. Oxidative stress and stress-activated signaling pathways: a unifying hypothesis of type 2 diabetes. Endocr Rev. 2002;23(5):599–622.CrossRef PubMed
  24.Griendling KK, FitzGerald GA. Oxidative stress and cardiovascular injury: part I: basic mechanisms and in vivo monitoring of ROS. Circulation. 2003;108(16):1912–6.CrossRef PubMed
  25.Burk RF, Hill KE. Selenoprotein P: an extracellular protein with unique physical characteristics and a role in selenium homeostasis. Annu Rev Nutr. 2005;25:215–35.CrossRef PubMed
  26.Steinbrenner H, Bilgic E, Alili L, et al. Selenoprotein P protects endothelial cells from oxidative damage by stimulation of glutathione peroxidase expression and activity. Free Radic Res. 2006;40(9):936–43.CrossRef PubMed
  27.Traulsen H, Steinbrenner H, Buchczyk DP, et al. Selenoprotein P protects low-density lipoprotein against oxidation. Free Radic Res. 2004;38(2):123–8.CrossRef PubMed
  28.Atkinson JB, Hill KE, Burk RF. Centrilobular endothelial cell injury by diquat in the selenium-deficient rat liver. Lab Investig. 2001;81(2):193–200.CrossRef PubMed
  29.Burk RF, Early DS, Hill KE, et al. Plasma selenium in patients with cirrhosis. Hepatology. 1998;27(3):794–8.CrossRef PubMed
  30.Cazzo E, Jimenez LS, Pareja JC, et al. Effect of Roux-en-y gastric bypass on nonalcoholic fatty liver disease evaluated through NAFLD fibrosis score: a prospective study. Obes Surg. 2014. doi:10.​1007/​s11695-014-1489-2 .
  31.Vargas V, Allende H, Lecube A, et al. Surgically induced weight loss by gastric bypass improves non alcoholic fatty liver disease in morbid obese patients. World J Hepatol. 2012;4(12):382–8.PubMed PubMedCentral
  
• 作者单位：Jisun Lim (1)
  Hye Soon Park (1)
  Seul Ki Lee (2)
  Yeon Jin Jang (2)
  Yeon Ji Lee (3)
  Yoonseok Heo (4)
  
  1. Department of Family Medicine, University of Ulsan College of Medicine, 88, Olympic-Ro 43-Gil, Songpa-gu, Seoul, 138-736, South Korea
  2. Department of Physiology, University of Ulsan College of Medicine, 88, Olympic-Ro 43-Gil, Songpa-gu, Seoul, 138-736, South Korea
  3. Department of Family Medicine, College of Medicine, Inha University, 7-206, Sinheung-dong 3-Ga, Jung-gu, Incheon, 400-711, South Korea
  4. Department of General Surgery, College of Medicine, Inha University, 7-206, Sinheung-dong 3-Ga, Jung-gu, Incheon, 400-711, South Korea
  
• 刊物主题：Surgery;
• 出版者：Springer US
• ISSN：1708-0428

文摘

Background Bariatric surgery has beneficial effects on weight loss and metabolic profiles. Recent evidence suggests that liver-derived hepatokines play a role in the pathophysiology of metabolic diseases. However, few studies have reported longitudinal changes in hepatokines after gastric bypass surgery. We investigated changes in the serum levels of angiopoietin-like protein 6 (Angptl6) and selenoprotein P after gastric bypass surgery.